|
1. Biologie
|
|
|
Study reveals subtypes of lymphoma [NIH]
|
|
|
|
|
|
The
research team analyzed genomic alterations and gene expression in tumor
samples from 574 people with DLBCL. They identified four prominent
subtypes that each share a group of genetic aberrations. People with two
of the subtypes, called BN2 and EZB, respond well to treatment. People
with the other two, called MCD and N1, don’t.
|
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
F.D.A. Cracks Down on Sales of E-Cigarettes to Minors [NY Times]
|
|
|
|
|
|
Schools
across the country say they were blindsided by the number of students
turning up with Juuls last fall. Nicknamed the iPhone of e-cigarettes,
Juuls resemble thumb drives, produce little plume, and smell like fruit
or other flavorings, making them so concealable that students can vape
in class.
|
|
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
EU reviewing MSD’s Keytruda/chemo combo [PharmaTimes]
|
|
|
|
|
|
The
filing is based on data from the Phase III KEYNOTE-189 trial, which
showed that first-line use of Keytruda (pembrolizumab) in combination
with pemetrexed (Lilly’s Alimta) and cisplatin or carboplatin slashed
the risk of death by 51 percent compared with chemotherapy alone.
|
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
How Blueprint Medicines Got The Blues [Forbes]
|
|
|
|
|
|
The
numbers Blueprint had presented included cases where doctors had not
double-checked to make sure the tumors had really shrunk enough to be
called responses. Drilon subtracted those out. This lowered the response
rate in medullary thyroid patients from 40% to 24%, and in non-small
cell lung cancer from 50% to 36%.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
5.9 AACR
|
|
|
A cancer drug tailored to your tumor? Experts trade barbs over ‘precision oncology’ [Science]
|
|
|
|
|
|
On
one side was David Hyman, a 30-something oncologist at Memorial Sloan
Kettering Cancer Center in New York City and a leader of clinical
studies testing gene-targeted cancer drugs. Genomics won’t help most
cancer patients at this point, he acknowledged, but many do clearly
benefit: “I think this is certainly not hype,” Hyman said. Countering
Hyman was another young oncologist, Vinay Prasad of Oregon Health &
Science University in Portland, a prolific author of provocative journal
articles and outspoken Twitter commentator with more than 17,000
followers.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
6.10 Politiques
|
|
|
Windrush scandal: Albert Thompson gets cancer treatment date [The Guardian]
|
|
|
|
|
|
Thompson,
63, said he was “very excited” to hear that a 33-day radiotherapy
programme was scheduled to start on 1 May, but was surprised by the
sudden rush to resolve the situation after six months of extreme
anxiety. “They are scared of all the publicity in the media; it has
really shaken them up,” he said.
|
|
|
|
|
|